Fund managers said Australia?s second-largest pathology group, Healius Limited (ASX:HLS), is vulnerable to being picked off by private equity buyers as it accelerates a strategic review after the departure of chief executive Maxine Jaquet. Ms Jaquet has left the top job, effective immediately, after a collapse in profits and margins. Healius announced that chief financial officer Paul Anderson, a former CEO of Network Ten, will take over, expediting a strategic review of the business and examining potential asset sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.435 AUD | -4.33% |
|
-4.01% | -12.23% |
06-26 | Jarden Research Adjusts Healius' Price Target to AU$1.22 From AU$1.26, Keeps at Underweight | MT |
06-25 | Healius Lowers Fiscal 2024 Earnings Guidance | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.23% | 727M | |
-20.01% | 8.43B | |
+68.39% | 4.35B | |
+9.54% | 2.78B | |
-1.93% | 2.64B | |
-13.91% | 1.77B | |
-56.42% | 1.74B | |
-14.80% | 1.48B | |
+22.44% | 1.22B | |
-50.02% | 1.02B |
- Stock Market
- Equities
- HLS Stock
- News Healius Limited
- Healius Accelerates Strategic Review